Clinical Pharmacologist, Pharmaceutica ldepartment, Usl Umbria 1, Via XIV Settembre, 06132 Perugia, Italy.
Hospital Pharmacist Manager, Pharmaceutical department, Asl Napoli 3 Sud, Nola, Dell'amicizia street 22, 80035 Naples, Italy.
J Reprod Immunol. 2022 Jun;151:103630. doi: 10.1016/j.jri.2022.103630. Epub 2022 Apr 21.
The global pandemic of COVID-19 is currently ongoing. Clinical evidence shows that specific population groups such as the elderly, individuals with comorbidities, and pregnant women may be at increased risk for infection and serious complications. In particular, physiologic changes during pregnancy may be significant on the immune and respiratory systems and progression of COVID-19 disease. Pregnant women are routinely excluded from pre-registration clinical trials, this potentially limits their access to therapies through off-label or compassionate use. Vaccination remains an important pillar of the response to COVID-19, particularly as variants of the virus continue to spread across countries. Growing evidence indicates that COVID-19 mRNA vaccines do not cause pregnancy complications for expectant mothers and their infants. In this brief review, we explore current knowledge about COVID-19 in pregnancy by highlighting current recommendations for vaccination and drug treatments.
目前,COVID-19 正在全球大流行。临床证据表明,老年人、患有合并症的个体和孕妇等特定人群群体可能面临更高的感染和严重并发症风险。特别是,怀孕期间的生理变化可能会对免疫系统和呼吸系统以及 COVID-19 疾病的进展产生重大影响。孕妇通常被排除在预先登记的临床试验之外,这可能会限制她们通过标签外使用或同情用药获得治疗的机会。疫苗接种仍然是应对 COVID-19 的重要支柱,特别是因为病毒的变体继续在各国传播。越来越多的证据表明,COVID-19 mRNA 疫苗不会给孕妇及其婴儿带来妊娠并发症。在这篇简短的综述中,我们通过强调当前的疫苗接种和药物治疗建议,探讨了怀孕期间 COVID-19 的现有知识。